论文部分内容阅读
目的 :比较主动循环与单灌单抽腹腔热灌注化疗治疗卵巢癌腹腔积液的疗效。方法 :将2016年3月—2017年5月接受主动循环腹腔热灌注化疗的53例卵巢癌腹腔积液患者作为研究组,2015年7月—2016年2月接受单灌单抽腹腔热灌注化疗的51例卵巢癌腹腔积液患者作为对照组。2组患者均接受紫杉醇联合顺铂方案化疗,每次治疗时进行3次热灌注,共治疗2个周期。比较2组灌注液进入腹腔和抽出腹腔时的温度、持续时间和治疗效果。结果 :2组灌注液进入腹腔的温度阈值均可控制为43.0~43.5℃。研究组灌注液出腹温度为41.0~41.5℃,且温度维持恒定。研究组患者腹腔积液治疗有效率为86.8%(46/53),对照组为64.7%(33/51),2组的差异有统计学意义(P<0.05)。除腹痛以外,2组不良反应发生率的差异无统计学意义(P值均>0.05)。结论:主动循环腹腔热灌注化疗治疗卵巢癌腹腔积液时的温度恒定、治疗时间短、安全性高且疗效显著,值得在临床上予以推广。
Objective: To compare the curative effect of active circulation and single irrigation with intraperitoneal hyperthermic perfusion chemotherapy in the treatment of ovarian cancer with ascites. Methods: From March 2016 to May 2017, 53 patients with active ascites peritoneal hyperthermic chemoradiotherapy were enrolled as study group. From July 2015 to February 2016, patients undergoing single-perfused intraperitoneal hyperthermic perfusion chemotherapy 51 cases of ovarian cancer patients with ascites as a control group. Both groups received paclitaxel combined with cisplatin regimen chemotherapy, three times per treatment hot perfusion, a total of 2 cycles. The temperature, duration and therapeutic effect of two groups of perfusate into the abdominal cavity and abdominal cavity were compared. Results: The temperature threshold of peritoneal perfusion fluid in both groups could be controlled to 43.0 ~ 43.5 ℃. The study group perfusion liquid abdomen temperature was 41.0 ~ 41.5 ℃, and the temperature remained constant. The study group, the efficiency of ascites effusion was 86.8% (46/53), the control group was 64.7% (33/51), the difference between the two groups was statistically significant (P <0.05). Except abdominal pain, there was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: The active circulating intraperitoneal hyperthermic perfusion chemotherapy for the treatment of ovarian cancer ascites fluid temperature is constant, the treatment time is short, high safety and significant effect, it is worth to be promoted in the clinic.